Reconstitution of lyophilised peptides: difference between revisions
Diff·revision 13 → 14·14:58, 28 Nov 2024
Difference between revision 13 and revision 14 of Reconstitution of lyophilised peptides. 16 lines changed; the page grew by 558 bytes.
| Revision 13 — 13:52, 12 Nov 2024 DeadSpaceDot (talk) give the worked example to two significant figures throughout 3,118 bytes ±0 | Revision 14 — 14:58, 28 Nov 2024 LeanMassLars (talk) sentence case in headings per PP:MOS 3,676 bytes +558 | ||
|---|---|---|---|
| 23 | Visual inspection after dissolution is informative. A clear, colourless solution free of visible particles is the expected result; haze, particles or fibrous material indicate that the material has changed, whatever the certificate said about the powder. See [[Peptide aggregation]].{{r|usp1503}} | 23 | Visual inspection after dissolution is informative. A clear, colourless solution free of visible particles is the expected result; haze, particles or fibrous material indicate that the material has changed, whatever the certificate said about the powder. See [[Peptide aggregation]].{{r|usp1503}} |
| 24 | 24 | ||
| + | 25 | == Concentration arithmetic == | |
| + | 26 | Concentration is peptide mass divided by diluent volume. The volume displaced by a few milligrams of solid is negligible at ordinary scales, so added volume can be treated as final volume without material error.{{r|usp1503}} | |
| + | 27 | ||
| + | 28 | | Nominal fill | Diluent | Nominal concentration | | |
| + | 29 | |---|---|---| | |
| + | 30 | | 5 mg | 1.0 mL | 5 mg/mL | | |
| + | 31 | | 5 mg | 2.0 mL | 2.5 mg/mL | | |
| + | 32 | | 10 mg | 2.0 mL | 5 mg/mL | | |
| + | 33 | | 2 mg | 1.0 mL | 2 mg/mL | | |
| + | 34 | ||
| 25 | == References == | 35 | == References == |
| 26 | {{reflist}} | 36 | {{reflist}} |
| ⋮ | ⋮ | ||
| 28 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 38 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 29 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> | 39 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> |
| + | 40 | ||
| + | 41 | == See also == | |
| + | 42 | * [[Lyophilisation]] | |
| + | 43 | * [[Bacteriostatic water]] | |
| + | 44 | * [[Sterile water for injection]] | |
| + | 45 | * [[Beyond-use date]] | |
| 30 | 46 | ||
| 31 | {{DEFAULTSORT:Reconstitution of lyophilised peptides}} | 47 | {{DEFAULTSORT:Reconstitution of lyophilised peptides}} |